With interactions such as direct protein-protein agonism increasingly seen as targets for therapeutic intervention [67], identification of new cofactors, such as ZFP407, in the PPARγ pathway can reveal new drug targets for insulin resistance and T2D. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.